Floatz logo

PYRAZOLO(3,4-D)AZEPINE, 3-(4-CHLOROPHENYL)-1,4,5,6,7,8-HEXAHYDRO-1-(PHENYLMETHYL)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1) (SALT)

Major Depressive Disorder

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

235 Active assets in the Major Depressive Disorder cohort.

Asset / SponsorPhaseRating
Risperdal
Johns Hopkins University
Phase 4BBB
Zelapar
Corium Innovations, Inc.
Phase 4BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
Opc-34712
Nova Scotia Health Authority
Phase 4BBB

View all 50 →

Same molecule, other indications

PYRAZOLO(3,4-D)AZEPINE, 3-(4-CHLOROPHENYL)-1,4,5,6,7,8-HEXAHYDRO-1-(PHENYLMETHYL)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1) (SALT) is also rated in:

bipolar disorderDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →